EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.

Abstract

EpCAM might be a novel cancer stem cell marker in RB. EpCAM×CD3 antibody redirecting T cells to attack RB tumor cells may prove effective in RB management. Further preclinical studies are needed to confirm the initial findings of our study.